Efficacy and safety of fibroblast growth factor 21 analogs in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and network meta-analysis.

MK-3655 - Merck (MSD)

efruxifermin (AKR-001) - Novo Nordisk

pegozafermin (BIO89-100) - 89Bio

http://www.ncbi.nlm.nih.gov/pubmed/41529428

Amira Mohamed Taha; Areeba Fareed; Khaled Abouelmagd; Marwa Muhammed Abdeljawad; Menna Keshk; Misha Khan; Mohammed Tarek Hasan; Nouran A Taha; Sara Adel Abdelkader Saed; Shujaat Ali

Jan 14, 2026